Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERPSIS: NBI-1065846 in MDD with Anhedonia
NCT05165394Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of zelatriazin in major depressive disorder (MDD), sponsored by Neurocrine Biosciences. Started Nov 2021; status: completed.
02
Drugs
zelatriazin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05165394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165394.